Detalhe da pesquisa
1.
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study.
Am J Hematol
; 98(3): 449-463, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36594167
2.
Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
MAbs
; 13(1): 1862452, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33382956
3.
ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1.
Oncotarget
; 7(18): 25103-12, 2016 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27029064
4.
Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.
Nat Chem
; 8(12): 1112-1119, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27874860
5.
A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Clin Cancer Res
; 21(14): 3298-306, 2015 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25840969
6.
DCDT2980S, an anti-CD22-monomethyl auristatin E antibody-drug conjugate, is a potential treatment for non-Hodgkin lymphoma.
Mol Cancer Ther
; 12(7): 1255-65, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23598530
7.
FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma.
Mol Cancer Ther
; 11(10): 2222-32, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22807577